Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Jazz Pharmaceuticals

Biotech & Life Sciences · Dublin, Ireland · Founded 2003 · IPO 2007 Decacorn

Identifying, developing and commercializing meaningful products that address unmet medical needs

Valuation
$16B
Market cap · May/2026
Revenue
$4.27B
Latest reported FY
EBITDA
$2.04B
Latest reported FY

Investors

8 investors on Jazz Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 7 investors entered at this stage
Golden Gate Capital
Thoma Cressey Equity Partners
Adams Street Partners
EGS Healthcare Capital Partners
Lehman Brothers
Beecken Petty O'Keefe & Company
Prospect Venture Partners

Global footprint

Where Jazz Pharmaceuticals has talent and traffic

AI talent share
0.5% of workforce is AI talent
(19 of 3,627 staff)
Core AI10.03%
Other AI180.5%
Non-AI workforce3,60899.48%
Workforce by country
33 countries with
team presence
🇺🇸 United States54.1%
🇬🇧 United Kingdom21.1%
🇮🇪 Ireland7.2%
🇮🇹 Italy4.2%
🇨🇦 Canada2.8%
Top 5 of 33 shown
Web traffic by country
81K monthly visits
across markets
🇺🇸 United States46.7%
🇬🇧 United Kingdom13.6%
🇮🇪 Ireland7.3%
🇮🇳 India5.9%
🇳🇬 Nigeria4.4%
Top 5 markets shown

Patent intelligence

$300M patent portfolio · 149 active families

Estimated portfolio value
$300M
1.9% of market cap · 1.8× the top peer Amicus Therapeutics ($164M)
149 active patent families
Where Jazz Pharmaceuticals innovates PharmacologyMedicinal chemistryDrugCannabidiolCannabivarin

Where Jazz Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Jazz Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Jazz Pharmaceuticals's 12 investments and acquisitions.

Every disclosed deal where Jazz Pharmaceuticals appeared as a backer or acquirer, 2012–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

12 deals across Jazz Pharmaceuticals's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Jazz Pharmaceuticals's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        12 of 12 deals

        Market sentiment

        What the market is saying about Jazz Pharmaceuticals

        An AI-synthesized read of the highest-engagement posts about Jazz Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Jazz Pharmaceuticals on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.